報價延遲最少15分鐘:2024/04/27 15:58 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.41 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.38/-2.54
|
|
企業價值
609.25M
|
| 資產負債 |
|
每股賬面淨值
3.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
0.18
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/04/27 15:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S. |